|drug688||Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Wiki||0.71|
|drug926||artus Influenza A/B RT-PCR Test Wiki||0.71|
|drug122||Biological: COVID-19 convalescent plasma Wiki||0.71|
|drug151||COVID-19 RT-PCR Wiki||0.41|
|D003384||Coxsackievirus Infections NIH||0.71|
|D018184||Paramyxoviridae Infections NIH||0.41|
|D018357||Respiratory Syncytial Virus Infections NIH||0.35|
|D007251||Influenza, Human NIH||0.27|
|D003141||Communicable Diseases NIH||0.08|
|D014777||Virus Diseases NIH||0.08|
|D018352||Coronavirus Infections NIH||0.04|
There are 2 clinical trials
The study will be conducted using nasopharyngeal swab specimens collected prospectively from individuals suspected of having the signs and symptoms of an acute respiratory tract infection caused by a respiratory virus. A series of standard viral culture tests validated for routine use in the clinical laboratory, and/or a series of PCR-based Laboratory Developed Tests (PCR-LDT) validated by a central reference laboratory will be used to verify the performance of the investigational artus Influenza A/B RT-PCR test and the QIAGEN ResPlex II Advanced Panel test. From each specimen five (5) aliquots will be prepared: (a) one aliquot will be tested in real-time using the assigned viral culture reference methods; (b) one aliquot will be used to extract nucleic acid in real-time for investigational testing; (c) one aliquot of the specimen will be stored at --70C for subsequent shipment to the reference laboratory for PCR-LDT testing, (d) one aliquot will be archived at -70C for subsequent follow-up by the reference laboratory (e.g., bi-directional sequencing of positive specimens), and (e) any remaining specimen will be stored for the Fresh vs. Frozen Study. The extracted nucleic acid generated from the second aliquot (i.e., "b" above) will be split and subjected to testing by both the artus Influenza A/B RT-PCR test and the ResPlex II Advanced Panel test.
Description: The presence of Influenza A or Influenza B virus.Measure: Detection of Respiratory Viruses Time: Specimens will be taken within 5 days of the appearance of symptoms.
This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of SARS-CoV-2.